AGENDA AT A GLANCE
8:30
Registration & Coffee
Scaling Next-Gen Biologics in DACH
9:00
Opening Keynote: Advancing Personalising vaccines for commercial success – moving towards phase 3
- Scaling personalised vaccine platforms towards Phase III readiness
- Manufacturing, supply chain, and regulatory considerations for commercialisation
- Translating clinical promise into sustainable, real-world impact
10:40
Networking Break
Continuous/Intensified Manufacturing
12:30
Lunch Break
Advances in Downstream Processing
13:30
Efficiency Unleashed: Fully Automated Self-Optimizing Screening in Process Development - Unlocking the Potential of Microbial Systems
- Fully automated, self-optimising screening to accelerate process development
- Leveraging microbial systems for faster data-driven decision making
- Reducing development timelines while maximising process performance
15:10
When Process Intensification Hits the Patient: Manufacturing Trends Driving the Next Generation of High‑Dose Subcutaneous Biologics
- Process intensification strategies enabling high-dose subcutaneous biologics
- Manufacturing and formulation challenges impacting patient delivery
- Translating manufacturing innovation into improved patient experience
15:35
Networking Break
16:00
Roundtable Discussions
- Navigating Global Policy Shifts in Biologics Procurement - How evolving US and EU policies are reshaping sourcing strategies for biologics and advanced therapies.
- Strategic Shifts in Biologics Supply Chains
- AI & Future Biomanufacturing Facilities Design
- Stainless Vs disposable Equipment & Components
- What systems are we talking about? – latest disposables developments and experiences
- What comparative cost and environmental impact calculations are true?
- Impact of PFAS regulations and mitigation measures
- Vendor dependence
17:00
Key Takeaways
17:15
Drink Reception & End of Day 1
Quality Assurance & Process Intensification
9:10
Process Intensification and Lifecycle Management Strategy of Biopharmaceuticals Post Launch
- Applying process intensification to enhance efficiency and robustness post-launch
- Managing lifecycle changes while maintaining regulatory compliance
- Driving continuous improvement across commercial biopharmaceutical manufacturing
9:35
Process Intensification Opportunities, Challenges and Solutions: Product Quality, Harvest and Scale up Considerations for Intensified Processes
- Key opportunities and challenges in implementing intensified bioprocesses
- Impact on product quality, harvest strategies, and process control
- Practical considerations for scale-up and operational robustness
10:00
Networking Break
Single-Use & Facility Strategies
10:30
11:20
Intensification by Design: Integrated Continuous Biomanufacturing for Viral Vector Processes
- Designing integrated continuous platforms for viral vector manufacturing
- Benefits of intensification across productivity, consistency, and facility footprint
- Technical and regulatory considerations for continuous viral vector processes
11:45
Lunch Break
Manufacturing Innovations for Allogeneic and In Vivo Therapies
13:00
CARKey™ – A multi-specific, dual receptor CAR T platform to overcome solid tumour antigen heterogeneity
- Addressing solid tumour antigen heterogeneity through multi-specific CAR T design
- Dual-receptor architecture to enhance targeting and therapeutic efficacy
- Platform potential for broader applicability across solid tumour indications
13:50
Networking Break
Smart Factories: The Role of Digitalisation & AI
Supply Chain & Logistics
16:30
Chairman’s Closing Rearks
16:30
END OF CONFERENCE
